Preclinical and Translational Sciences - Chemical

(T0930-10-63) Cognitive Impairment on the Physicochemical Characteristics of Fasting Gastric Contents of Individuals in Advanced Age: Initial Data

(T0930-10-64) Pharmacokinetic Studies of 7-hydroxymitragynine, the Active Metabolite of Mitragynine, in Rats

(T0930-10-65) Human Renal Clearance Prediction Using Monkey

(T0930-10-66) Impact of Aging on Relative Gene Expression of Tight Junction Proteins in Duodenal and Colonic Epithelium: Preliminary Data

(T0930-10-67) A Sensitive and Specific Human Primary Stem Cell-Based In Vitro Assay for Predicting Gastrointestinal Toxicity Risk

(M0930-10-67) Past-to-Present Comparison of Repeat Analysis-Related Observations in Pharmacokinetic Bioequivalence Studies Submitted in Abbreviated New Drug Applications

(W0930-10-67) Utilizing PBPK Absorption Modeling to Evaluate Impact of Single-Sex on Bioequivalence Evaluation of Atorvastatin Immediate Release Tablets

(M0930-10-68) Focus on Efficacy: In Vitro Tissue Models for Preclinical Research

(T0930-10-68) Investigating the Mechanism of Synergism of Pyrazinamide When Administered in Combination with Spectinamide 1599 in Murine TB Models

(W0930-10-68) Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict the Pharmacokinetics of Pantoprazole According to CYP2C19 Genetic Polymorphism

(W0930-10-69) Islatravir Does Not Partition to Red Blood Cells: An In Vitro Study to Support a Total Drug Assay in Dried Blood

(M0930-10-69) Mechanistic Modeling of In Vitro Biopharmaceutic Experiments for a Weakly Dibasic Drug for Incorporation into PBPK Models

(T0930-10-69) Optimizing Carvedilol Dosing Following Gastric Bypass Surgery Using Population-Based PK/PD Modeling

(W1030-10-64) 3D Bioprinted Artificial Buccal Mucosal Membranes: A Single Platform for Conducting Permeation, Efficacy and Safety Testing of Treatment Modalities for Oral Cavity Disorders

(W1030-10-65) Clinical Evaluations of Potential CYP450 Inhibition by Radix Puerariae lobatae (Gegen) in Healthy Subjects

(T1030-10-66) Identifying Critical Parameters for Physiological Based Pharmacokinetic Modeling of Naloxone Hydrochloride Nasal Sprays

(M1030-10-66) Integrating Herbal Medicine into Modern Practice: Nonclinical Evaluation of Cinnamomum cassia Extract and Extrapolation from Animals to Humans

(W1030-10-66) Model Development and Verification of Mechanistic Long-Acting Suspension-Based Injectable Model

(T1030-10-67) Pharmacokinetic Characterization of ETN101, a Novel Anti-cancer Agent and Its Metabolites in Rats and Dogs

(T1030-10-68) Machine Learning-Based Prediction of Aldehyde Oxidase Activity in Multiple Species

(M1030-10-68) Plasma Pharmacokinetics and Tissue Disposition of Cefoxitin in an Animal Model of Obesity

(M1030-10-69) Elucidation of Interaction Mechanisms between Irinotecan and Oroxylin A in Rats through Physiologically Based Pharmacokinetic Modeling

(T1030-10-69) Evaluating the Relative Contribution of OATP2B1 Transporter on Rosuvastatin Pharmacokinetic Drug-Drug Interactions Using Mechanistic and Physiologically Based Pharmacokinetic Modeling

(W1130-10-63) Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict the Pharmacokinetics of Pitavastatin in Different SLCO1B1 Diplotypes

(T1130-10-63) Retrospective Safety Evaluation of Tyrosine Kinase Inhibitor Products When Administered in Single Dose in Crossover Studies to Healthy Volunteers

(M1130-10-64) Effect of Amounts of DMSO and Incubation Time on BBB-PAMPA Permeability of Drugs with High and Low BBB Permeability

(T1130-10-64) Explore Gender Differences in Perfluorooctanoic Acid Using Ontogeny Integrated Physiologically-Based Pharmacokinetic Model in Rats

(W1130-10-64) Refining Predictions of Food Effects on Drug Absorption: Models Predicting Gastric Emptying and Bile Concentrations Based on Fat Content and Caloric Intake

(W1130-10-65) Development and Validation of a Physiologically Based Pharmacokinetic Model of Tofacitinib in Mice to Predict Dosing in Higher Animal Species

(T1130-10-66) Factors Affecting Peripheral Neuropathy Induced by Nab-paclitaxel in Patients with Pancreatic Cancer

(M1130-10-66) Pharmacokinetics of Mitragynine, a Kratom Alkaloid, in Pregnant Rats: Implications for Maternal and Fetal Health

(T1130-10-67) Development of a Novel HPLC Method for the Sensitive Detection of Quercetin and Related Flavonoids in the Treatment of Myotonic Dystrophy

(W1130-10-67) Effects of Abcb1 and Abcg2 on the Brain Penetration, Biliary Disposition, and Intestinal Secretion of the PI3K Inhibitor Taselisib

(M1130-10-67) Model Based Analysis for Determining Bioequivalence of Metronidazole Topical Cream

(W1130-10-68) Development of Stable Flocculated Suspension Formulation for Preclinical Studies

(T1130-10-69) Identification of Drug Metabolizing Enzymes that Catalyze Formation of a Novel Oxidative Metabolite from 7-ethoxycoumarin

(W1130-10-69) Pharmacokinetics, Excretion, and Metabolism of [¹⁴C]Aficamten Following Single Oral Dose Administration to Rats

(M1130-10-69) Tissue Engineered Human 3D Tumor Model Portfolio Reflecting In Vivo Characteristics for Eficacy Assessment of Preclinical Anti-cancer Therapy In Vitro

(W1230-10-63) Clarifying the Impact of Advanced Age on the Physicochemical Characteristics of Gastric Contents in the Fasted State

(T1230-10-63) TV-46000, a Novel Long Acting Injectable (LAI) Formulation of Risperidone, Forms a Stable and Robust Subcutaneous Depot, Even under Extreme Conditions: Prediction from Dog and Minipig to Human

(T1230-10-64) Scientific and Regulatory Considerations of Applying Morphologically Directed Raman Spectroscopy in Bioequivalence Assessment for Generic Orally Inhaled and Nasal Drug Products

(M1230-10-65) Pharmacokinetic Characterization of a Novel COVID-19 Inhibitor OJT010 in a Rat Model

(T1230-10-66) Addressing the MicroSampling Sensitivity Challenge in DMPK Studies Using Vacuum Jacketed Column UHPLC-cyclic Ion Mobility MS

(M1230-10-66) Assessment of the Effect of Resmetirom, a Liver-Directed, Orally Active, Selective Thyroid Hormone Receptor-β Agonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects

(W1230-10-67) Development of In Vitro In Vivo Correlation for Establishing Clinically Relevant Dissolution Specifications of Lamotrigine ER Tablets

(T1230-10-67) Pharmacokinetic Profiles of Paynantheine and Its Diastereomer, Isopaynantheine, in Sprague-Dawley Rats

(M1230-10-67) Rivaroxaban Pharmacokinetics after Single Oral Dose in Obese Subjects: An Open-Label Controlled Clinical Trial

(W1230-10-68) A Phase 1, Open-Label, Single-Period, Nonrandomized Study of the Pharmacokinetics, Excretion, Mass Balance and Metabolism of Oral [¹⁴C] PF-07265803 (ARRY-371797) in Healthy Male Adults

(T1230-10-68) Mechanistic Elucidation of Pharmacokinetic Effects of Target-Mediated Drug Disposition (TMDD) for Small Molecule VAP-1 Inhibitor

(T1230-10-69) Metabolite Identification of Nucleoside Analog Prodrugs in Biological Matrix by Derivatization Coupled with Radio-Detector and Mass Spectrometry

(T1330-10-67) Assay Development and Characterization of T. gondii Nucleoside Transporters in MDCK-II Cells

(M1330-10-67) Population Pharmacokinetic Model of Tacrolimus in Brazilian Bone Marrow Transplantation Patients: A Tool for Dosing Regimen Optimization

(T1330-10-68) Effects of Clarithromycin on the Pharmacokinetics of Pitavastatin and Its Lactone Metabolite in Different SLCO1B1 Diplotypes

(T1330-10-69) Evaluation of Applications for Topical Semisolid Drug Products with In Vitro Permeation Test and In Vivo Bioequivalence Study with Pharmacokinetic Endpoints

(T1430-10-63) Impact of Preparation Technique and Storage Condition on the Quality of Suspension Vehicles Used in Preclinical In Vivo Studies

(T1430-10-64) Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics

(M1430-10-64) Physiologically Based Biopharmaceutics Modeling of BCS Class I Extended-Release Drug Products: A Preliminary Exploration

(T1430-10-66) Pharmacokinetics of Nervonic Acid, a Monounsaturated Fatty, in an Adrenoleukodystrophy (ALD) Mouse Model

(M1430-10-67) Effect of Food on the Pharmacokinetics of Mitragynine in Rats

(T1430-10-68) Metabolite Identification of R14 in Rat Urine after a Single Oral Administration to Rats Using UPLC-TOF MS/MS

(M1430-10-68) Physiologically-Based Pharmacokinetic (PBPK) Modeling of Oral Absorption of 5-flucytosine to Support Development of a Sustained-Release Formulation for Treatment of Cryptococcal Meningoencephalitis

(M1430-10-69) Disposition and Metabolism of the Cardiac Myosin Inhibitor Aficamten in Humans

(T1430-10-69) Using Simulation to Address Challenges in Bioequivalence Data Analysis for Drug Products Containing Endogenous Compounds

(T1530-10-67) Ex Vivo Platforms (Perfused Liver/Kidney and Intestinal Tissue) including PBPK Modeling Enabling Human PK Predictions and Metabolite Synthesis

(M1530-10-67) Preclinical Pharmacokinetic Study and Lung Penetration of Coumarin Extracted of Zanthoxylum tingoassuiba

(M1530-10-68) Assessing the In Vitro Performance of Solid Dosage Forms Over-Encapsulated with the ID-Cap System for Improved Compliance

(T1530-10-68) In Silico Predictive Modeling of the Pharmacokinetic (PK) Profiles of Nasal Sprays in Adults and Children

(M1530-10-69) A Simulation-Based Decision Guide to Evaluate Missing Data in Bioequivalence Studies

(T1530-10-69) Evidence-Based Strategies for the Characterization of New Chemical Entity (NCE) In Vitro CYP and Non-CYP Enzyme Reaction Phenotyping at the Development Stage